Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Estradiol Valerate

FDA-approved product (injectable, injection), marketed as Delestrogen, Estradiol Valerate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Estradiol Valerate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atrophic Vaginitis
  • Atrophy
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Dyspareunia
  • Hypogonadism
  • Menopause
  • Menorrhagia
  • Osteoporosis
  • Postmenopausal atrophic vaginitis
  • Postmenopausal osteoporosis
  • Premature ovarian insufficiency
  • Primary ovarian insufficiency

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Natural and semisynthetic estrogens, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis22.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Estradiol Valerate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Estradiol Valerate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Hormonal Birth Control and the Risk of Acquiring HIV

    NCT00006324 · start 1999-12

    Registered record
    Registry ID
    NCT00006324
    Conditions
    HIV Infections
    Interventions
    Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1999-12
    Completion
    2002-12
    Enrolment
    6,360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionEthinyl estradiol/levonorgestrel; Medroxyprogesterone acetate
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Antiseizure Medication on Hormone Levels and Sexual Function in Men With Epilepsy

    NCT00179426 · start 1999-10

    Registered record
    Registry ID
    NCT00179426
    Conditions
    Seizure Disorder; Epilepsy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    1999-10
    Completion
    2006-06
    Enrolment
    175

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeizure Disorder; Epilepsy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

    NCT00003633 · start 1998-08

    Registered record
    Registry ID
    NCT00003633
    Conditions
    Prostate Cancer
    Interventions
    docetaxel; estramustine phosphate sodium; mitoxantrone hydrochloride; prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    1998-08
    Completion
    Not recorded
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventiondocetaxel; estramustine phosphate sodium; mitoxantrone hydrochloride; prednisone
    PhasePhase 1
    Registry statusUnknown

  • Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

    NCT00001521 · start 1995-06-08

    Registered record
    Registry ID
    NCT00001521
    Conditions
    Congenital Adrenal Hyperplasia (CAH)
    Interventions
    Fludrocortisone; Hydrocortisone; Letrozole; Flutamide; Testolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-06-08
    Completion
    2024-04-01
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Adrenal Hyperplasia (CAH)
    InterventionFludrocortisone; Hydrocortisone; Letrozole; Flutamide +1 more
    PhasePhase 3
    Registry statusCompleted

  • Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women

    NCT00044837

    Registered record
    Registry ID
    NCT00044837
    Conditions
    HIV Infections
    Interventions
    Medroxyprogesterone acetate; Estradiol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionMedroxyprogesterone acetate; Estradiol
    PhasePhase 1
    Registry statusTerminated